Results 91 to 100 of about 526 (127)

Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy). [PDF]

Indian J Ophthalmol
Verma L, Singh S, Talwar D, Gupta A, Khare G, Ramachandran ON, Bhanupriya, Gujral GS, Harish HS, Gupta N.   +9 more
europepmc   +1 more source

Characteristics of pachychoroid neovasculopathy

, 2021
openaire   +1 more source

Comparison of Choroidal Morphological Changes Between Aflibercept 8 mg and Faricimab-svoa in Treatment-Naïve Polypoidal Choroidal Vasculopathy and Pachychoroid Neovasculopathy. [PDF]

J Clin Med
Jeong S, Seong SH, Sagong M.
europepmc   +1 more source

Author Correction: Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. [PDF]

Sci Rep, 2021
Yoon J, Yoon W, Na SK, Lee J, Kim CG, Kim JW, Cho HJ.   +6 more
europepmc   +1 more source

Efficiency of anti-VEGF therapy for pachychoroidal neovasculopathy

Modern technologies in ophtalmology, 2020
U.S. Fayzieva, Z.R. Maksudova, N.A. Usmanova, G.A. Rakhmanova   +3 more
openaire   +1 more source

Pachychoroid Neovasculopathy Within The Spectrum of Pachychoroid Disease

Trends in Ophthalmology Open Access Journal, 2018
openaire   +1 more source

Pachychoroid neovasculopathy and age-related macular degeneration.

Pachychoroid neovasculopathy and age-related macular degeneration.
Pachychoroid neovasculopathy is a recently proposed clinical entity of choroidal neovascularization (CNV). As it often masquerades as neovascular age-related macular degeneration (AMD), it is currently controversial whether pachychoroid neovasculopathy should be distinguished from neovascular AMD. This is because its characteristics have yet to be well
openaire  

One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy. [PDF]

Eye (Lond), 2021
Hikichi T, Kubo N, Yamauchi M.
europepmc   +1 more source

Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes. [PDF]

Graefes Arch Clin Exp Ophthalmol
Tanaka N, Azuma K, Aoki S, Kitamoto K, Ueda K, Fujino R, Inoue T, Obata R.   +7 more
europepmc   +1 more source

Complement Activation Products and Cytokines in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration. [PDF]

Invest Ophthalmol Vis Sci, 2020
Kato Y, Oguchi Y, Omori T, Shintake H, Tomita R, Kasai A, Ogasawara M, Sugano Y, Itagaki K, Ojima A, Machida T, Sekine H, Sekiryu T.   +12 more
europepmc   +1 more source